⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BLTE News
Belite Bio, Inc American Depositary Shares
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
globenewswire.com
BLTE
Belite Bio to Participate in Four Upcoming Investor Conferences
globenewswire.com
BLTE
Belite Bio to Host Virtual Commercial Day on September 2, 2026
globenewswire.com
BLTE
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
globenewswire.com
BLTE
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
globenewswire.com
BLTE
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
globenewswire.com
BLTE
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
globenewswire.com
BLTE
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
globenewswire.com
BLTE
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
globenewswire.com
BLTE
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
globenewswire.com
BLTE